Docket #: S11-031

Neuregulin Antagonists and Use Thereof in Treating Cancer

A method of using neuregulin antagonists to delay the time of tumor recurrence in cancer patients has been developed by Dr. Sweet-Cordero and collaborators. This technology is available for non-exclusive license. For many cancer patients disease recurrence after chemotherapy is a major cause of mortality. This relapse and recurrence is caused by tumor-reinitiating cells (TRICs). Neuregulin autocrine signaling plays an important role in the survival and proliferation of TRICs, thus antagonizing neuregulin signaling can delay the time to tumor recurrence.

Applications

- Delay tumor recurrence.
- Potential additional uses include:
    - Prevent tumor recurrence
    - Prevent chemotherapeutic resistance
    - Treat chemotherapeutic resistant cancer

Advantages

- Extend the time to tumor recurrence.

Publications

- US patent application 13/029,199: Neuregulin antagonists and use thereof in treating cancer

Patents

- Published Application: 20110229493

Innovators

- Eric Alejandro Sweet-Cordero
- Erica Jackson

Licensing Contact

Mona Wan

Senior Licensing Manager for Special Projects

Email